IDEXX Laboratories, Inc. vs SiTime Corporation — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while SiTime Corporation trades at $612.37 (market cap $19.42B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.1× SiTime Corporation's market cap, and SiTime Corporation is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and SiTime Corporation for 18 Days on average.
| IDXX | SITM | |
|---|---|---|
Market Cap | $40.43B | $19.42B |
Volume | 692,164 | 360,307 |
Sector | Health | Technology |
52-Week High | $766.68 | $901.60 |
52-Week Low | $504.70 | $252.76 |
Typical Hold Time | 46 Days | 18 Days |
Enterprise Value | $41.32B | $18.82B |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.27 exceeding the $3.94 estimate. Revenue grew to $4.3 billion in 2025, and net income margin expanded to 25.03%. Recent acquisitions like CoVetAI aim to enhance veterinary workflow intelligence.
The outlook remains positive given robust profitability and analyst consensus, but risks include foreign exchange headwinds and competitive pressures. With a consensus price target of $665, representing ~30% upside, the stock offers growth potential for investors comfortable with its premium valuation multiples.
SITM trades at $645.06, down 3.02% today but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $628 and $610, while fundamental metrics highlight accelerating revenue growth from $327M in 2025 to $468M in 2026, though profitability remains volatile with recent net income turning positive. Analyst sentiment remains overwhelmingly positive with 100% buy ratings and a $751.43 consensus target.
SITM presents compelling growth potential driven by AI infrastructure demand and market leadership in precision timing solutions, though investors face risks from valuation multiples and competitive pressures. The company's inflection toward profitability and strong institutional support suggest upside potential, but requires monitoring of execution risks and market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →